Regulatory Update

Atlanta – September 22, 2026 -- Georgia Power and Google have filed a new agreement with the Georgia Public Service Commission that ties Google's subscription to nuclear capacity uprates at Plants Hatch and Vogtle, a move projected to deliver approximately $900 million in customer benefits over the life of the units.

Google subscription funds 96 megawatts of new nuclear capacity

The filings, submitted under Docket 44280 and Docket 56002, detail how Google's support for extended power uprates (EPUs) at Georgia Power's owned nuclear units will add roughly 96 megawatts of capacity to the state grid. The agreement requires PSC approval and introduces a new Nuclear Uprate (NU-1) tariff structure.

Washington – September 22, 2026 -- The Teamsters Union has endorsed a settlement agreement announced by California Attorney General Rob Bonta that clears a path for the pending merger between Paramount Skydance and Warner Bros. Discovery.

Bonta brokers deal covering unions and employers in entertainment merger

Teamsters General President Sean M. O'Brien credited Attorney General Bonta for coordinating unions, employers, and other stakeholders to reach terms on the merger. The union identified worker protections embedded in the agreement as the central issue for its 1.3 million members across the U.S., Canada, and Puerto Rico.

Seattle – September 22, 2026 -- Glacis Technologies has agreed to transfer stewardship of OVERT, its open technical specification for verifying AI safeguards at runtime, to the Coalition for Health AI (CHAI) and the AIGovOps Foundation.

Glacis relinquishes sole control of the specification it created

Under the agreement announced today, CHAI and AIGovOps will jointly oversee the OVERT standard once a separate commencement certificate signed by all three parties takes effect. Glacis, the Seattle-based company that developed OVERT, will initially maintain the specification and operate its registry, but will act only as a non-voting editor once stewardship transfers.

Waltham, Mass. – September 22, 2026 -- The U.S. Food and Drug Administration has approved Mercy BioAnalytics' Investigational Device Exemption application for its Evident Ovarian Cancer Screening Test, clearing the way for the company's pivotal SOARA Clinical Validation Study pending Institutional Review Board sign-off.

FDA clears IDE application for Mercy's Evident Ovarian Cancer Screening Test

The approval permits Mercy to launch the prospective SOARA study -- Safety in Ovarian Cancer for Average-Risk Women, Analysis -- to evaluate the safety of the blood-based test in average-risk women. The IDE clearance does not constitute FDA approval or clearance of the Evident test itself, but authorizes the specified clinical investigation to proceed.

Idaho Falls – September 21, 2026 -- Construction projects in Eastern Idaho frequently require a stack of approvals beyond the standard building permit, including well permits, septic system reviews, driveway access clearances, utility connection permits, and floodplain reviews, according to insights from Ren Ferguson of Copper Creek Homes published by HelloNation.

Rural properties depend on private well and septic approvals instead of municipal utilities

Many properties across Eastern Idaho rely on private water and wastewater systems rather than city infrastructure. A well permit confirms proper placement and water quality, while septic system approval requires soil evaluations and detailed site plans reviewed by local health districts before foundation work can proceed.

Jerusalem – September 21, 2026 -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) has regained compliance with Nasdaq's $1.00 minimum bid price rule after its American Depositary Shares closed at or above that threshold for 19 consecutive business days, Nasdaq Listing Qualifications confirmed in a September 18, 2026 letter.

Nasdaq closes compliance matter after ADS price clears threshold for 19 sessions

The closing bid price of Scinai's ADSs met or exceeded $1.00 per share from August 21, 2026 through September 17, 2026, satisfying Nasdaq Listing Rule 5550(a)(2). Nasdaq had first flagged the deficiency on March 12, 2026, after the ADSs failed to maintain the $1.00 minimum over the prior 30 consecutive business days.

CEO says resolution shifts focus to CDMO commercial execution

"Receiving Nasdaq's confirmation closes an important compliance matter for Scinai,

Bridgewater, N.J. – September 21, 2026 -- The U.S. Food and Drug Administration has accepted Insmed Incorporated's supplemental New Drug Application (sNDA) for full approval of ARIKAYCE (amikacin liposome inhalation suspension) to treat Mycobacterium avium complex (MAC) lung disease, granting Priority Review with a PDUFA target action date of January 28, 2027.

FDA sets January 28, 2027 decision date under Priority Review

The Priority Review designation applies to therapies that could offer significant improvement in safety or efficacy for serious conditions. Insmed said full approval would allow ARIKAYCE, administered via PARI Pharma's Lamira Nebulizer System, to reach patients earlier in their disease course, including newly diagnosed cases and those with recurrent infections.

Germantown, Md. – September 21, 2026 -- The U.S. Food and Drug Administration has granted platform technology designation to Precigen's AdenoVerse immunotherapeutic platform, the technology underlying the company's first commercial product, PAPZIMEOS, approved in August 2025 for recurrent respiratory papillomatosis (RRP) in adults.

FDA designation opens accelerated pathway for future AdenoVerse cancer programs

The designation allows Precigen to leverage manufacturing and preclinical data generated for PAPZIMEOS to support future marketing applications for other AdenoVerse-based candidates, reducing duplicative development work. It also grants the company earlier and more frequent FDA engagement and allows regulators to consider prior manufacturing inspections when reviewing future applications.

New Taipei City – September 21, 2026 -- UD info's DB Series SSD Drives have achieved FIPS 140-3 validation from the National Institute of Standards and Technology's Cryptographic Module Validation Program, with NIST Certificate No. 5479 issued August 12, 2026, confirming Overall Level 2 status.

Certificate confirms Overall Level 2 validation for DB Series cryptographic module

The validation provides independent third-party assurance that the DB Series meets federal cryptographic security requirements, addressing procurement mandates in government, critical infrastructure, and other regulated sectors. NIST CMVP validation is a common prerequisite for federal and defense-adjacent storage procurement in the United States.

Beijing – September 21, 2026 -- Chinese President Xi Jinping has ordered sustained expansion of advanced manufacturing, calling for smart, green and integrated industrial upgrading to strengthen supply-chain self-sufficiency, according to instructions conveyed at a national conference on advanced manufacturing in Beijing reported by Xinhua News Agency.

Xi, who also chairs the Central Military Commission, said industrial chains must become more self-supporting and risk-resilient while pursuing higher-quality development and greater security. Premier Li Qiang told the conference that developing advanced manufacturing must be treated as a major strategic task.